Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
AOD 9604 targets only peripheral fat metabolism without affecting the GH axis, making it relevant to investigational protocols in which isolated lipolytic activity is the objective and systemic GH effects are not required
There may be some side effects, especially with the digestive system, he says
Yeo and colleagues explained that with rising obesity in the U.S., the increasing prevalence of GLP-1 receptor agonists prescribed for obesity may contribute to drug shortages. Further, drug shortages may exacerbate the existing nationwide racial and ethnic disparities in GLP-1 receptor agonist prescriptions, they wrote, adding that the results suggest a call for strategies to address the growing demand and ensure equitable access to the drugs.
Participants could include sponsors of Part D stand-alone prescription drug plans (PDPs) and Medicare Advantage prescription drug plans (MA-PDs), including Special Needs Plans (SNPs), and employer plans that offer Part D
